Zhe Zhang

Dr. Zhe Zhang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Kidney Diseases
Verified
Journal Article
Open access
ZZZhe Zhang
Zhe Zhang
QCQiyan Chen
Qiyan Chen
WWWenting Wu
Wenting Wu
RTRuiling Tang
Ruiling Tang
CLCongwei Luo
Congwei Luo
HLHai-Bo Long
Hai-Bo Long
Objective: Diabetic nephropathy (DN), a critical complication of diabetes, is characterized by progressive renal function impairment and fibrosis development. F-box and WD repeat domain-containing 7 (FBXW7), an E3 ubiquitin ligase, is recognized for its role in metabolic disorders; however, its specific functions and mechanisms in DN remain incompletely understood. This study aimed to clarify the role of FBXW7 in the pathogenesis of DN. Methods: Mouse tubular epithelial cells (mTECs) cultured under hyperglycemic conditions were used. FBXW7 overexpression was induced in the kidneys of db/db mice and in mTECs to evaluate its effects on renal fibrosis and related molecular pathways. The interaction between FBXW7 and metadherin (Mtdh) was examined by using co-immunoprecipitation and Western blotting techniques. Results: FBXW7 expression was found to be significant reduced in the kidneys of DN patients and db/db mice. Overexpression of FBXW7 markedly improved albuminuria, blood urea nitrogen, uric acid levels, and renal fibrosis in db/db mice. Additionally, FBXW7 was shown to inhibit high glucose-induced fibrosis in mTECs through a mechanism involving the ubiquitin-mediated degradation of Mtdh, a protein known to promote fibrosis. Suppression of Mtdh via FBXW7 overexpression was also linked to inactivation of TGF-β/Smad3 signaling in DN. Conclusion: These findings highlight the protective role of FBXW7 in DN by downregulating Mtdh and indicate that FBXW7 represents a promising therapeutic target for DN.

13 June 2025 in Medicine
Verified
Journal Article
Open access
ZZZhe Zhang
Zhe Zhang
YLYunshi Lai
Yunshi Lai
XLXiaoyi Liu
Xiaoyi Liu
PYPeiyi Bd Ye
Peiyi Bd Ye
YKYaozhong Kong
Yaozhong Kong
CXChao Xie
Chao Xie
Rationale: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects various organs. Disease activity in SLE may diminish following the initiation of dialysis in patients with end-stage renal disease. Patient concern: We report the case of a 69-year-old female patient with a prior diagnosis of IgA nephropathy who developed SLE characterized by severe thrombocytopenia after hemodialysis. Diagnoses: The patient presented with fever, rash, polyarthralgia, thrombocytopenia, hemolytic anemia, positive antinuclear antibodies, anti-nucleosome antibodies, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies, and decreased complement C3 and C4 levels. She was diagnosed with SLE complicated by hematological damage and immune thrombocytopenia. Interventions: The treatment included an intravenous infusion of 5% human immunoglobulin at 20 g/day for 5 days combined with an intravenous infusion of methylprednisolone at 500 mg/day for 3 days. Plasma exchange therapy was conducted a total of 3 times. Outcomes: The patient was discharged with methylprednisolone and hydroxychloroquine treatment. The platelet count was stable, antinuclear antibody, anti-nucleosome antibody, antiphospholipid antibody, Coombs test, and complement C3 and C4 levels were normal after discharge. Lessons: In patients with unexplained thrombocytopenia, the possibility of SLE should be considered even after hemodialysis initiation.